Actively Recruiting
Gene Therapy for Subjects With RPGR Mutation-associated X-linked Retinitis Pigmentosa
Led by Frontera Therapeutics · Updated on 2023-05-24
18
Participants Needed
2
Research Sites
247 weeks
Total Duration
On this page
Sponsors
F
Frontera Therapeutics
Lead Sponsor
E
Eye & ENT Hospital of Fudan University
Collaborating Sponsor
AI-Summary
What this Trial Is About
A clinical trial of gene therapy for patients with X-linked retinitis pigmentosa (XLRP).
CONDITIONS
Official Title
Gene Therapy for Subjects With RPGR Mutation-associated X-linked Retinitis Pigmentosa
Who Can Participate
Eligibility Criteria
You may qualify if you...
- Willing and able to follow study procedures
- Male aged 8 to 45 years at the time of signing the Informed Consent Form
- Confirmed variants of RPGR gene
You will not qualify if you...
- Other retinal degenerative diseases caused by known inherited retinal disease gene variants
- Previous treatment with any gene therapy product
AI-Screening
AI-Powered Screening
Complete this quick 3-step screening to check your eligibility
Trial Site Locations
Total: 2 locations
1
Peking Union Medical College Hospital
Beijing, Beijing Municipality, China, 100142
Actively Recruiting
2
Eye & ENT hospital of Fudan university
Shanghai, Shanghai Municipality, China, 200032
Actively Recruiting
Research Team
X
Xinyan Li
CONTACT
M
Minghui Xue
CONTACT
How is the study designed?
Study Type
INTERVENTIONAL
Masking
NONE
Allocation
NON_RANDOMIZED
Model
SEQUENTIAL
Primary Purpose
TREATMENT
Number of Arms
3
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here